Open an account

Journey Medical

DERM · NASDAQ

$5.22+$0.05 (+0.97%)TodayMarket closed ·
Prev close $5.17

About DERM

Journey Medical Corp. is a commercial-stage pharmaceutical company, which focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions. The company is headquartered in Scottsdale, Arizona and currently employs 58 full-time employees. The company went IPO on 2021-11-12. The firm is focused on selling and marketing of the United States Food and Drug Administration (FDA) approved prescription pharmaceutical products for the treatment of dermatological conditions. Its portfolio includes eight FDA-approved prescription drugs for dermatological conditions that are marketed in the United States. Its marketed products, which have been approved FDA for sale in the United States, include Qbrexza, Accutane, Amzeeq, Zilxi, Exelderm Cream and Solution, Targadox, and Luxamend. Qbrexza is a medicated cloth towelette for the treatment of primary axillary hyperhidrosis. Accutane is an oral isotretinoin drug for the treatment of severe recalcitrant nodular acne. Targadox is an oral doxycycline drug for adjunctive therapy for severe acne. Luxamend is a water-based emulsion formulated to provide moist healing environment.

Employees
58
Headquarters
Scottsdale, Arizona
Listed
Nov 12, 2021
Sector
Health Care
Industry
Pharmaceuticals
Website
journeymedicalcorp.com

DERM key statistics

Market cap
145.92M
Price-earnings ratio
0.00
Dividend yield
—
Average volume
208.37K
Volume
312.80K
Open price
$5.21
High today
$5.39
Low today
$5.13
52 Week high
$9.56
52 Week low
$4.31

Journey Medical (DERM) at a glance

As of Oct 20, 2026, Journey Medical (DERM) shares are priced at $5.22, giving the company a market cap of 145.92M and a price-to-earnings ratio of 0.00.

Today the stock has traded between $5.13 and $5.39. The current price is 1.8% above the day's low and 3.2% below its high.

Volume so far is 312.80K shares, above the average of 208.37K shares a day.

Over the past year Journey Medical has ranged from $4.31 to $9.56, and now sits 17% of the way up that range.

Journey Medical met or beat analyst EPS estimates in 4 of the last 8 quarters. In Q2 FY26 it reported -$0.01 per share against an estimate of -$0.0229.

The average analyst price target is $14.79, 183.3% above the current price, from 2 recent ratings.

Analyst ratings

Latest rating from each analyst over the past 12 months

100%of 2 analyst ratings say Buy
  • Buy100.0%
  • Hold0.0%
  • Sell0.0%
Price target · 4 analystsAvg $14.79
Low
$14.14
Now
$5.22
High
$15.75

DERM earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 4 of the last 8 quarters, by 40.5% on average.

  1. Q3 FY24: reported -$0.17 per share against an estimate of -$0.1505
  2. Q4 FY24: reported -$0.15 per share against an estimate of -$0.3596
  3. Q1 FY25: reported -$0.18 per share against an estimate of -$0.2423
  4. Q2 FY25: reported -$0.16 per share against an estimate of -$0.1071
  5. Q3 FY25: reported -$0.09 per share against an estimate of -$0.0485
  6. Q4 FY25: reported -$0.046 per share against an estimate of -$0.0587
  7. Q1 FY26: reported -$0.08 per share against an estimate of -$0.0791
  8. Q2 FY26: reported -$0.01 per share against an estimate of -$0.0229

DERM news

  • Press releaseGlobe Newswire

    Journey Medical Corporation to Participate in September 2026 Investor Conferences

  • 12 Health Care Stocks Moving In Thursday's Pre-Market Session

  • Press releaseGlobe Newswire

    Journey Medical Corporation Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights

  • Press releaseGlobe Newswire

    Journey Medical Corporation to Announce Second Quarter 2026 Financial Results on August 12, 2026

  • Transcript: Journey Medical Q1 2026 Earnings Conference Call

  • Press releaseGlobe Newswire

    Journey Medical Corporation Reports First Quarter 2026 Financial Results and Recent Corporate Highlights

  • Press releaseGlobe Newswire

    Journey Medical Corporation to Announce First Quarter 2026 Financial Results on May 13, 2026

  • Press releasePRNewswire

    INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Journey Medical Corporation - DERM

Similar companies

Companies in the same industry as Journey Medical

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.